Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.33 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974332 | 0.84 | DGAT1 (0.36) | NPC1KLKB1DGAT1EGFRIGF1R | |
| SCHEMBL16679708 | 0.79 | DGAT1 (0.43) | NPC1KLKB1DGAT1EGFRIGF1R | |
| SCHEMBL200911 | 0.74 | NPC1 (0.41) | NPC1KLKB1DGAT1EGFRIGF1R | |
| SCHEMBL16680416 | 0.72 | DGAT1 (0.45) | DGAT1BRD4 | |
| SCHEMBL30165149 | 0.72 | ALDH1A1 (0.40) | NPC1KLKB1DGAT1EGFRIGF1R | |
| SCHEMBL7831021 | 0.70 | UPP1 (0.51) | EGFRIGF1RSRCFLT4KDR | |
| SCHEMBL6041792 | 0.70 | BRD4 (0.36) | NPC1DGAT1BRD4 | |
| SCHEMBL6042106 | 0.70 | NPC1 (0.37) | NPC1DGAT1BRD4 | |
| SCHEMBL22143174 | 0.70 | DGAT1 (0.67) | DGAT1 | |
| SCHEMBL22121980 | 0.70 | DGAT1 (0.43) | KLKB1DGAT1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609699-B2 | Oxotetrahydrofuran-2-yl-benzimidazole derivative | MSD K.K. (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2328892-B1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20110144162-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-06-16 | — | — | US | disclosed |
| EP-2328892-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | MSD K.K. (JP) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010024110-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144162-A1 | OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE | GCK, GCKR, KHK | TYR 338/4885NPC1 2556/4885KLKB1 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.